Sovran Advisors’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$2.55M Buy
2,731
+844
+45% +$856K 0.2% 122
2025
Q4
$1.95M Sell
1,887
-225
-11% -$215K 0.17% 139
2025
Q3
$1.78M Buy
2,112
+441
+26% +$328K 0.16% 144
2025
Q2
$1.3M Buy
1,671
+664
+66% +$516K 0.14% 169
2025
Q1
$846K Buy
1,007
+504
+100% +$419K 0.11% 200
2024
Q4
$375K Buy
+503
New +$416K 0.05% 306

Other funds holding LLY

Sovran Advisors's LLY Position: Q1 2026 in Review

Sovran Advisors increased its Eli Lilly (LLY) stake by 45% in Q1 2026, buying an estimated $856K and bringing the position to 2,731 shares worth $2.55M. The position accounts for 0.2% of the portfolio, ranked #122.

Sovran Advisors first reported a position in LLY in Q4 2024 and has held it in 6 quarters since. 4,354 funds tracked by Wall St. Rank hold LLY as of Q1 2026.

  • Sovran Advisors held 2,731 shares of Eli Lilly worth $2.55M as of Q1 2026.
  • Sovran Advisors bought 844 Eli Lilly shares in Q1 2026, an estimated $856K.
  • Eli Lilly made up 0.2% of Sovran Advisors's portfolio in Q1 2026, its #122 holding.
  • Sovran Advisors first reported a position in Eli Lilly in Q4 2024 and has held it in 6 quarters since.
  • 4,354 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.

Based on Sovran Advisors's 13F filing for Q1 2026, filed 1 May 2026.